Cargando…
Inhibition of GSK3 by lithium, from single molecules to signaling networks
For more than 60 years, the mood stabilizer lithium has been used alone or in combination for the treatment of bipolar disorder, schizophrenia, depression, and other mental illnesses. Despite this long history, the molecular mechanisms trough which lithium regulates behavior are still poorly underst...
Autores principales: | Freland, Laure, Beaulieu, Jean-Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3282483/ https://www.ncbi.nlm.nih.gov/pubmed/22363263 http://dx.doi.org/10.3389/fnmol.2012.00014 |
Ejemplares similares
-
Inhibition of glycogen synthase kinase 3 by lithium, a mechanism in search of specificity
por: Chatterjee, Dipashree, et al.
Publicado: (2022) -
Neurological Functions of the Masterswitch Protein Kinase – Gsk-3
por: Kaidanovich-Beilin, Oksana, et al.
Publicado: (2012) -
Beyond cAMP: The Regulation of Akt and GSK3 by Dopamine Receptors
por: Beaulieu, Jean-Martin, et al.
Publicado: (2011) -
Lithium Inhibits GSK3β and Augments GluN2A Receptor Expression in the Prefrontal Cortex
por: Monaco, Sarah A., et al.
Publicado: (2018) -
AKT/GSK3 signaling pathway and schizophrenia
por: Emamian, Effat S.
Publicado: (2012)